75566 Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices 

Element Resources, Inc., Highlands 

Ranch, CO; Re:Build Manufacturing 

Solutions LLC, Framingham, MA; 

Reecycle, Inc., New York, NY; 

ReElement Technologies LLC, Fishers, 

IN; Relativity Space, Long Beach, CA; 

ReLogic Research, Inc., Huntsville, AL; 

Resin Solutions LLC, Hermosa Beach, 

CA; Rhea Space Activity, Inc., 

Washington, DC; Ring of Fire Metals Pty 

Ltd, Toronto, CANADA; Rio Tinto 

Services, Inc., South Jordan, UT; Saab, 

Inc., East Syracuse, NY; Safaricross, 

Westerville, OH; Safire Technology 

Group, Inc., Tysons, VA; Salesforce 

COM, San Francisco, CA; San Diego 

Regenerative Medicine Institute, San 

Diego, CA; Santor Security, Inc., 

Montreal-Nord, CANADA; SAS 

MANUFACTURING LLC, Boulder, CO; 

Savor Foods Limited, San Jose, CA; SB 

Boron Corp., Bellwood, IL; Scale Free 

Solutions LLC, Keyser, WV; Science 

Spark, Encinitas, CA; Scope 

Technologies US, Inc., San Francisco, 

CA; Sensor Technology Ltd., 

Collingwood, CANADA; Silicon 

Technologies, Inc., Midvale, UT; 

Simulation Technologies, Inc., 

Huntsville, AL; Sintavia, Hollywood, 

FL; SkyWater Technology Foundry, Inc., 

Bloomington, MN; SMI Solutions, Inc., 

Huntington, WV; Soldier Systems D– 

MIL LLC, Gilsum, NH; Solugen, Inc., 

Houston, TX; Songhi Innovations, 

Fountain, CO; South Dakota School of 

Mines and Technology, Rapid City, SD; 

Southern Cross Aviation LLC, Fort 

Lauderdale, FL; Space Engine Systems, 

Inc., Edmonton, CANADA; SPARC 

Research LLC, Warrenton, VA; Spectral 

Sciences, Inc., Burlington, MA; SRL 

Metals Pty Ltd, Melbourne, 

AUSTRALIA; Steel Founders’ Society of 

America, Crystal Lake, IL; Stephenson 

Endeavors Corp., Shreveport, LA; 

Stephenson Stellar Corp., Shreveport, 

LA; STI Electronics, Inc., Madison, AL; 

Stratolaunch LLC, Mojave, CA; STS 

International, Berkeley Springs, WV; 

Syndicate 708 LLC, Poway, CA; 

Synonym, Inc., New York, NY; Systima 

Technologies, Mukilteo, WA; Syzygy 

Integration LLC, Conshohocken, PA; 

T.G.V. Rockets, Inc., Washington, DC; 

Tandem Repeat Technologies, Inc., State 

College, PA; TechNext, Inc., Richmond, 

MA; Teck Resources Limited, 

Vancouver, CANADA; Terves LLC, 

Euclid, OH; Tex-Tech Coatings LLC, 

Kernersville, NC; Textum OPCO LLC, 

Belmont, NC; Thaler Machine Company 

LLC, Springsboro, OH; Thales Australia 

Ltd., Sydney Olympic Park, 

AUSTRALIA; The Better Meat Co., West 

Sacramento, CA; The Fynder Group, 

Inc., Chicago, IL; The Johns Hopkins 

University, Baltimore, MD; The 

Saskatchewan Research Council, 

Saskatoon, CANADA; Thomas Global 

Systems LLC, Irvine, CA; Toray 

Composite Materials America, Inc., 

Tacoma, WA; Trusted Semiconductor 

Solutions, Brooklyn Park, MN; TTM 

Technologies, Inc., Santa Ana, CA; 

Tungsten West PLC, Plymouth, GREAT 

BRITAIN; UI Labs dba MxD USA, 

Chicago, IL; Umbra Lab, Inc., Santa 

Barbara, CA; Universal Technical 

Resource Services, Inc., Cherry Hill, NJ; 

University of British Columbia—Survive 

and Thrive Applied Research (STAR), 

Kelowna, CANADA; University of 

Florida, Gainesville, FL; Up Doppler 

Consulting LLC, Leonardtown, MD; 

Ursa Major Technologies, Inc., 

Berthoud, CO; Utron Kinetics, 

Manassas, VA; Valdos Consulting LLC, 

Coraopolis, PA; Valley Tech Systems, 

Inc., Folsom, CA; VanDeMark Chemical, 

Inc., Lockport, NY; VeriTX Corp., 

Amherst, NY; VerTechs Enterprise, Inc., 

El Cajon, CA; Veterans Legacy Health 

Alliance, Inc., Houston, TX; Virginia 

Tech Applied Research Corp., 

Arlington, VA; Visolis, Inc., Hayward, 

CA; Vulcan Elements LLC, Cambridge, 

MA; Wecoso, Inc., Huntington Beach, 

CA; Wichita State University, Wichita, 

KS; Wiley Companies, Coshocton, OH; 

WingXpand, Inc., St. Louis, MO; Wodin, 

Inc., Bedford Heights, OH; Wright 

Electric, Inc., Malta, NY; XR 2 LEAD 

LLC, Dumfries, VA; York laboratories 

LLC, York, PA; Zeteo Tech, Inc., 

Sykesville, MD; and ZymoChem, Inc., 

San Leandro, CA, have been added as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and DIBC intends 

to file additional written notifications 

disclosing all changes in membership. 

On February 21, 2024, DIBC filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on June 24, 2024 (89 FR 52508). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–20965 Filed 9–13–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Medical Technology 

Enterprise Consortium 

Notice is hereby given that, on June 

28, 2024, pursuant to section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), Medical Technology 

Enterprise Consortium (‘‘MTEC’’) has 

filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Able Hands Rehabilitation 

PC, Old Bridge, NJ; Atlantic Diving 

Supply, Inc. dba ADS, Inc., Virginia 

Beach, VA; BC3 Technologies, Inc., 

Baltimore, MD; Bessel LLC, El Paso, TX; 

BioTechnique LLC, York, PA; Black 

Canyon Consulting LLC, Fairfax, VA; 

Bruder Consulting & Venture Group, 

Franklin Lakes, NJ; Burrell International 

Group, Washington, DC; Coagulo 

Medical Technologies, Inc., 

Auburndale, MA; Cresilon, Inc., 

Brooklyn, NY; Drul, Inc., Baltimore, 

MD; Dynocarida, Inc., Newton, MA; 

Emergency Dermal Solutions LLC, 

Durango, CO; EverGlade Consulting 

LLC, Houston, TX; Excentium, Inc., 

Reston, VA; FEI.COM, Inc. dba Systems, 

Columbia, MD; Field Viewers, Inc., 

Austin, TX; FieldLine, Inc., Boulder, 

CO; GenAssist, Inc., St. Louis, MO; 

Glacier Support Service LLC, San 

Antonio, TX; iFyber LLC, Ithaca, NY; J 

& D Pharmaceuticals LLC, Monmouth 

Beach, NJ; Jaktool, Cranbury, NJ; 

KardioGenics, Inc., San Jose, CA; 

LifeRaft Drones, Inc., Fort Worth, TX; 

Mimosa Diagnostics, Inc., Toronto, 

CANADA; Mountain Biometrics, Salt 

Lake City, UT; Nano PharmaSolutions, 

Inc., San Diego, CA; Neuro42, Inc., San 

Francisco, CA;, neuroFit, Inc., Mountain 

View, CA;, Noxsano, Inc., Cincinnati, 

OH; NxTech, Inc., Attleboro, MA; 

Octapharma USA, Paramus, NJ; Okineo 

LLC, San Mateo, CA; Orthomod LLC, 

Dayton, OH; Overjet, Boston, MA; 

People Value Research, Ltd., Ipswich, 

UNITED KINGDOM; RxMP 

Therapeutics, Inc., Seattle, WA;, Safi 

Biotherapeutics, Inc., Cambridge, MA; 

Sherpani LLC, Baltimore, MD; Shionogi, 

Inc., Florham Park, NJ; Signum 

Technologies, Inc., Radnor, PA; The 

Emmes Company LLC, Rockville, MD; 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices 75567 

1The restrictions that the ALJ recommends 

imposing on Respondent’s registration require her 

to: (1) limit her controlled substance administering, 

prescribing, and dispensing to the practice of 

anesthesiology; (2) comply with the terms of the 

Medical Board of California’s (MBC’s) Stipulated 

Interim Order imposing restrictions on her 

Registration; (3) comply with the terms of her 

probation with the MBC and refrain from seeking 

early termination of her probation; (4) notify DEA’s 

Los Angeles Field Division of any action taken 

against her license and immediately surrender her 

Registration if her California medical license is 

suspended or revoked; (5) remain in monitoring for 

substance abuse and submit to regular urine drug 

screens; (6) provide DEA with copies of all 

quarterly reports issued by her practice monitor; (7) 

maintain a detailed record of controlled substances 

prescribed, administered, or dispensed; (8) report 

all activity involving Schedule II controlled 

substances to DEA on a monthly basis; (9) allow 

DEA personnel to enter her registered location 

during normal business hours without prior notice 

or a warrant. RD, at 42–43. 

2The Agency adopts the ALJ’s summary of each 

of the witnesses’ testimonies as well as the ALJ’s 

assessment with respect to each of the witnesses’ 

credibility. RD, at 4–23. 

3The Agency agrees with the ALJ that 

Respondent’s testimony was ‘‘genuine and 

generally consistent,’’ despite Respondent having a 

significant personal interest in the outcome of these 

proceedings. RD, at 23. The ALJ found that ‘‘to the 

extent that [Respondent’s testimony] differs from 

the testimony of other testifying witnesses, [he 

would] consider her personal interest in this case, 

and [he would] give her testimony the weight that 

it deserves in light of other evidence and testimony 

presented during the hearing.’’ Id. The Agency 

agrees with the amount of weight that the ALJ 

afforded Respondent’s testimony. 

4Zolpidem is a Schedule IV controlled substance 

sold under the brand name Ambien. The generic 

name (zolpidem) is used in this decision. 

5 Diazepam is a Schedule IV controlled substance 

sold under the brand name Valium. The generic 

name (diazepam) is used in this decision. 

Trade and Investment Queensland, San 

Francisco, CA; TruGenomix Health, 

Inc., dba Polaris Genomics, 

Gaithersburg, MD; Unveil LLC, 

Cincinnati, OH; Ursus Medical Designs 

LLC, Pittsburgh, PA; and Vaxxas Pty, 

Ltd., Hamilton, AUSTRALIA, have been 

added as parties to this venture. 

Also, ImmersiveTouch, Inc., Chicago, 

IL; Neuromersive, Inc., Fort Worth, TX; 

Precisio Biotix Technologies, Dover, DE; 

and Sepsis Scout, Inc., San Francisco, 

CA, have withdrawn as parties to this 

venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and MTEC 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On May 9, 2014, MTEC filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on June 9, 2014(79 FR 32999). 

The last notification was filed with 

the Department on April 2, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on June 21, 2024(89 FR 52090). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–20967 Filed 9–13–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—America’s DataHub 

Consortium 

Notice is hereby given that, on June 

28, 2024, pursuant to section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), America’s DataHub 

Consortium (‘‘ADC’’) has filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, ADACEN FEDERAL LLC, 

Albuquerque, NM; AT Worthy 

Technology, Fairfax, VA; Brightquery, 

Inc., Irvine, CA; Careplots, Inc., 

Malvern, PA; CAS a division of 

American Chemical Society, Columbus, 

OH; Data Point LLC, Orange, NJ; Data 

Products LLC, Chicago, IL; Generative 

Medical, Inc., Palo Alto, CA; K8R 

Applications, Inc. dba Future Perfect 

Engineering, Seattle, WA; Node.Digital, 

Leesburg, VA; Omnicom Consulting 

Group, Inc., Tarrytown, NY; Polaron 

Technologies, Inc., Miamisburg, OH; 

Prism Lab at Cornell University, Ithaca, 

NY; and Vistra Communications LLC, 

Lutz, FL, have been added as parties to 

this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and ADC intends 

to file additional written notifications 

disclosing all changes in membership. 

On November 11, 2021, ADC filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on December 22, 2021 (86 FR 

72628). 

The last notification was filed with 

the Department on April 4, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on June 21, 2024 (89 FR 52092). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–20968 Filed 9–13–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. 23–31] 

Mary A. Vreeke, M.D.; Decision and 

Order 

On February 13, 2023, the Drug 

Enforcement Administration (DEA or 

Government) issued an Order to Show 

Cause (OSC) to Mary A. Vreeke, M.D. 

(Respondent), of Oxnard, CA. OSC, at 1, 

5. The OSC proposed the revocation of 

Respondent’s DEA Certificate of 

Registration (Registration) No. 

FV3660037, alleging that Respondent’s 

continued registration is inconsistent 

with the public interest. Id. at 1 (citing 

21 U.S.C. 823(g)(1), 824(a)(4)). 

A hearing was held before DEA 

Administrative Law Judge Paul E. 

Soeffing (the ALJ), who, on October 19, 

2023, issued his Recommended Rulings, 

Findings of Fact, Conclusions of Law, 

and Decision (Recommended Decision 

or RD). The RD recommended that 

Respondent’s Registration be suspended 

for six months, and then reinstated with 

restrictions to ensure that Respondent 

remains sober and continues with her 

current treatment program.1 RD, at 27. 

Neither party filed Exceptions to the RD. 

Having reviewed the entire record, the 

Agency adopts and hereby incorporates 

by reference the ALJ’s credibility 

findings,2 findings of fact, and 

conclusions of law, and clarifies and 

expands upon portions thereof herein. 

However, the Agency has determined 

that revocation is the appropriate 

sanction based on the egregiousness of 

Respondent’s conduct, her recidivism, 

and the Agency’s interests in deterring 

intentional violations of the Controlled 

Substances Act (CSA). 

I. Findings of Fact 

Respondent is an anesthesiologist 

currently practicing at St. John’s 

Hospital in Oxnard, California. 

Respondent testified that she has a 

substance abuse disorder that began 

with abusing alcohol in her mid-30s. 

RD, at 18; Tr. 234–35.3 Respondent later 

began abusing zolpidem 4 and 

diazepam 5 which she obtained without 

a prescription either from a friend or by 

going into Mexico. Tr. 235. Respondent 

was arrested and convicted in 2009 for 


lotter on DSK11XQN23PROD with NOTICES1